Juvena Therapeutics
Biopharma discovering novel protein-based therapeutics that promote tissue regeneration
At Juvena Therapeutics, we are progressively combining quantitative proteomics with computer vision analysis of high throughput microscopy through machine learning to catalyze bringing protein therapeutics to market to treat aging.
Visit website: https://www.juvenatherapeutics.com/
Details last updated 11-Feb-2020
People at Juvena Therapeutics
Juvena Therapeutics News
A new medicine called JUV-161 might help people with DM1, a rare muscle disease
Business Wire - 23-Jan-2024
It improved muscles and slowed down the disease in animals
Read more...Reason reports back from Age-Related Disease Therapeutics Summit 2023
Fight Aging! - 16-Jun-2023
Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years
Read more...Lifespan.io summarises the proceedings of the Buck Institute's Longevity Summit
Lifespan.io (LEAF) - 20-Jan-2023
Another reminder of the amount of research, with multiple approaches, about to go into clinical trials
Read more...Juvena Therapeutics receives $50M to uncover therapeutic links between secreted proteins and diseases
Biospace - 08-Nov-2022
Its a fully integrated approach for developing biologics for chronic and age-related diseases
Read more...LEAF interviews Hanadie Yousef, co-founder and CEO of Juvena Therapeutics
Lifespan.io (LEAF) - 11-Feb-2020
Muscle regeneration would have a huge hit on healthspan - getting people more mobile again
Read more...
